Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsJulius Y. Strauss, James L. Gulley, Christian S. Hinrichs
Life of this patent
Estimating the term…
Abstract
The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subject an agent that blocks PD-L1 and TGF-beta pathways, thereby inhibiting a malignancy associated with HPV in the subject.
Claims22
A method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subject an agent or combination of agents that blocks PD-L1 and TGF-beta pathways, thereby inhibiting a malignancy associated with HPV in the subject.
Dependencies are inferred from the claim text.